-transparent.png){kind=logo}
Thirty-three patients with advanced prostate cancer were prospectively randomized to receive either Bacillus Calmette-Guerin (BCG) adjuvant immunotherapy plus conventional therapy or conventional therapy alone. Conventional therapy consisted of estrogens or observation. There was a statistically significantly (p less than 0.05) longer survival in the 16 BCG-treated patients (42 weeks) than in the 17 control patients (29 weeks).
Related Publications
P D Guinan, and
T John, and
G Baumgartner, and
B Sundar, and
R J Ablin
October 1982,
Urology,
P D Guinan, and
T John, and
G Baumgartner, and
B Sundar, and
R J Ablin
June 1983,
Journal of surgical oncology,
P D Guinan, and
T John, and
G Baumgartner, and
B Sundar, and
R J Ablin
February 1983,
Urology,
P D Guinan, and
T John, and
G Baumgartner, and
B Sundar, and
R J Ablin
January 1977,
Tumori,
P D Guinan, and
T John, and
G Baumgartner, and
B Sundar, and
R J Ablin
January 1977,
Developments in biological standardization,
P D Guinan, and
T John, and
G Baumgartner, and
B Sundar, and
R J Ablin
June 1983,
Canadian Medical Association journal,
P D Guinan, and
T John, and
G Baumgartner, and
B Sundar, and
R J Ablin
September 1984,
Gan to kagaku ryoho. Cancer & chemotherapy,
P D Guinan, and
T John, and
G Baumgartner, and
B Sundar, and
R J Ablin
January 1978,
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
P D Guinan, and
T John, and
G Baumgartner, and
B Sundar, and
R J Ablin
April 1979,
Cancer,
P D Guinan, and
T John, and
G Baumgartner, and
B Sundar, and
R J Ablin
October 1984,
Canadian Medical Association journal,
